Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III, randomised, double blind, placebo controlled and open label phase, multicentre study to investigate the efficacy and safety of BTX-A-HAC NG in the treatment of moderate to severe glabellar lines, and assess the long term efficacy and safety of BTX-A-HAC NG following repeated treatments in this indication

Next Previous
Trial Profile

A phase III, randomised, double blind, placebo controlled and open label phase, multicentre study to investigate the efficacy and safety of BTX-A-HAC NG in the treatment of moderate to severe glabellar lines, and assess the long term efficacy and safety of BTX-A-HAC NG following repeated treatments in this indication

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Glabellar lines
  • Focus Registrational; Therapeutic Use
  • Sponsors Ipsen

Most Recent Events

  • 31 May 2022 According to a Galderma media release, Pooled data from two phase III studies (NCT02353871 and NCT02493946) will be presented at the upcoming International Master Course on Aging Science (IMCAS) World Congress 2022 in Paris from June 3-5, 2022.
  • 30 Jan 2017 Status changed from active, no longer recruiting to completed.
  • 27 May 2016 Planned End Date changed from 1 Mar 2017 to 1 Dec 2016.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top